13 New Drugs Pass Muster At The EMA, Dexamethasone Withdrawal Explained
New products from Paion, Arvelle, Incyte and many others have been recommended for approval by the European Medicines Agency. Meanwhile, the agency has explained why the EU marketing authorization application for Dexamethasone Taw, for treating COVID-19 patients, was withdrawn.
You may also be interested in...
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
European CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Novo Nordisk Divides R&D, Expects More Late-Stage Studies In 2021
Novo Nordisk’s newer GLP1 products for diabetes, Ozempic and Rybelsus, drove the company’s sales growth in 2020, and with its CSO retiring after a two-decade shift, internal appointments are made to lead a reorganized R&D function.